Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to compare any good and bad effects of using a combination of nivolumab (Opdivo®) and cabozantinib (Cabometyx®) in people with metastatic kidney cancer.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03635892
Study type Interventional
Source Memorial Sloan Kettering Cancer Center
Contact
Status Active, not recruiting
Phase Phase 2
Start date August 13, 2018
Completion date August 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04623502 - An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy N/A
Recruiting NCT05043090 - Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC Phase 3
Completed NCT02489695 - Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma Phase 2
Terminated NCT00098618 - Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer Phase 2
Withdrawn NCT04603365 - Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer Phase 2
Recruiting NCT05620134 - Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer Phase 1/Phase 2
Recruiting NCT04413123 - Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC Phase 2
Completed NCT00126503 - Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer Phase 1/Phase 2
Active, not recruiting NCT01767636 - Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Phase 2
Active, not recruiting NCT03541902 - Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma Phase 2
Recruiting NCT03866382 - Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors Phase 2
Terminated NCT02837991 - A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma Phase 1
Completed NCT00335556 - Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors Phase 2
Recruiting NCT04981509 - Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer Phase 2
Recruiting NCT04071223 - Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study Phase 2
Recruiting NCT00898365 - Study of Kidney Tumors in Younger Patients
Recruiting NCT06339138 - Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study
Not yet recruiting NCT06146777 - Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy Phase 3